UroGen Pharma Ltd. (URGN)
UroGen Pharma Ltd. Statistics
Share Statistics
UroGen Pharma Ltd. has 42.2M shares outstanding. The number of shares has increased by 23.67% in one year.
| Shares Outstanding | 42.2M |
| Shares Change (YoY) | 23.67% |
| Shares Change (QoQ) | 0.2% |
| Owned by Institutions (%) | 81.5% |
| Shares Floating | 34.99M |
| Failed to Deliver (FTD) Shares | 886 |
| FTD / Avg. Volume | 0.24% |
Short Selling Information
The latest short interest is 5.99M, so 14.2% of the outstanding shares have been sold short.
| Short Interest | 5.99M |
| Short % of Shares Out | 14.2% |
| Short % of Float | 16.4% |
| Short Ratio (days to cover) | 12.4 |
Valuation Ratios
The PE ratio is -4.23 and the forward PE ratio is -3.98. UroGen Pharma Ltd.'s PEG ratio is 0.16.
| PE Ratio | -4.23 |
| Forward PE | -3.98 |
| PS Ratio | 5.23 |
| Forward PS | 0.8 |
| PB Ratio | -6.63 |
| P/FCF Ratio | -5.65 |
| PEG Ratio | 0.16 |
Enterprise Valuation
UroGen Pharma Ltd. has an Enterprise Value (EV) of 436.91M.
| EV / Earnings | -4.27 |
| EV / Sales | 5.28 |
| EV / EBITDA | -6.84 |
| EV / EBIT | -6.67 |
| EV / FCF | -5.71 |
Financial Position
The company has a current ratio of 5.42, with a Debt / Equity ratio of -1.54.
| Current Ratio | 5.42 |
| Quick Ratio | 5.24 |
| Debt / Equity | -1.54 |
| Total Debt / Capitalization | 286.31 |
| Cash Flow / Debt | -0.76 |
| Interest Coverage | -4.45 |
Financial Efficiency
Return on equity (ROE) is 1.57% and return on capital (ROIC) is -194.7%.
| Return on Equity (ROE) | 1.57% |
| Return on Assets (ROA) | -0.57% |
| Return on Capital (ROIC) | -194.7% |
| Revenue Per Employee | 381.17K |
| Profits Per Employee | -471.17K |
| Employee Count | 217 |
| Asset Turnover | 0.46 |
| Inventory Turnover | 1.65 |
Taxes
| Income Tax | 3.92M |
| Effective Tax Rate | -0.04 |
Stock Price Statistics
The stock price has increased by -46.76% in the last 52 weeks. The beta is 1.09, so UroGen Pharma Ltd.'s price volatility has been higher than the market average.
| Beta | 1.09 |
| 52-Week Price Change | -46.76% |
| 50-Day Moving Average | 10.58 |
| 200-Day Moving Average | 13.03 |
| Relative Strength Index (RSI) | 35.88 |
| Average Volume (20 Days) | 372.69K |
Income Statement
In the last 12 months, UroGen Pharma Ltd. had revenue of 82.71M and earned -102.24M in profits. Earnings per share was -3.55.
| Revenue | 82.71M |
| Gross Profit | 73.35M |
| Operating Income | -65.54M |
| Net Income | -102.24M |
| EBITDA | -63.83M |
| EBIT | -65.54M |
| Earnings Per Share (EPS) | -3.55 |
Balance Sheet
The company has 95M in cash and 100.21M in debt, giving a net cash position of -5.21M.
| Cash & Cash Equivalents | 95M |
| Total Debt | 100.21M |
| Net Cash | -5.21M |
| Retained Earnings | -679.35M |
| Total Assets | 301.94M |
| Working Capital | 262.31M |
Cash Flow
In the last 12 months, operating cash flow was -76.38M and capital expenditures -194K, giving a free cash flow of -76.57M.
| Operating Cash Flow | -76.38M |
| Capital Expenditures | -194K |
| Free Cash Flow | -76.57M |
| FCF Per Share | -2.66 |
Margins
Gross margin is 88.68%, with operating and profit margins of -79.23% and -123.61%.
| Gross Margin | 88.68% |
| Operating Margin | -79.23% |
| Pretax Margin | -118.87% |
| Profit Margin | -123.61% |
| EBITDA Margin | -77.17% |
| EBIT Margin | -79.23% |
| FCF Margin | -92.57% |
Dividends & Yields
URGN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -37.53% |
| FCF Yield | -19.18% |
Analyst Forecast
The average price target for URGN is $31, which is 227.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $31 |
| Price Target Difference | 227.7% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -2.26 |
| Piotroski F-Score | 3 |